AAO

A panel of speakers demonstrated different ways technology and artificial intelligence (AI) could greatly expand access to glaucoma care.

ChatGPT bested Google in a blinded comparison of their answers to common oculoplastic questions.

Changes have been proposed to the quality payment program that could have ups and downs, but not, perhaps for some, until 2029.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina thickness.

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing number of biosimilar competitors.

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more youthful appearance, says AAO presenter.

In the threat versus opportunity session, Cecilia and Aaron Lee of the University of Washington staked out opposing positions.

Presenters at a myth breakers session at the American Academy of Ophthalmology took aim at some prevailing notions.

Patients self-identified as members of the minority group that the study was designed to enroll, according to Jeremiah Brown, M.D., of Retina Consultants of Texas, one of the lead ELEVATUM investigators. The study will yield a "treasure trove" of data, Brown said.

Medicare patients are more likely to receive aflibercept 2 mg over other anti-VEGF agents compared with commercially insured patients.

Enrollment goals for the U.S. part of the phase 4, open-label study of Vabysmo (faricimab) were 45% Black participants, 45% Hispanic participants and 10% Native American, Pacific Islander and Native Hawaiian, said Jeremiah Brown, M.D., a lead ELEVATUM investigator.

Children with serious eye conditions are at an increased risk of developing mental health conditions, including schizophrenia, anxiety, depression and bipolar.

George O. Waring, IV, M.D., discusses the latest technology improving eyesight for patients.

After expansion of Medicaid, there was a significant decrease in the low-income population with no healthcare coverage.

New research finds that the financial burden of treatment for age-related macular degeneration can lead to delayed or incomplete treatment and poor outcomes. Telehealth and remote monitoring could reduce gaps.

Precision medicine will lead to fewer cases of ocular cancers, earlier diagnosis, and more targeted and sight-saving treatments.

One patient had complications that resulted in no light perception — effectively, blindness — in the the treated eye.

In real-world experience, Tepezza benefits patients with moderate-to-service thyroid eye disease, but adverse events can lead to discontinuation.

Approximately one-third of the patients assigned to 16-week intervals of 8-mg formulation of Eylea changed to a 24-week interval during the second year of. the study, according results presented at the annual meeting of the American Academy of Ophthalmology. The PHOTON study enrolled people with diabetic macular edema.

Albert S. Khouri, M.D., a professor of ophthalmology at the Rutgers New Jersey Medical School, discusses teleophthalmology’s role in outreach efforts and improving ophthalmic care in the emergency room.

Albert S. Khouri, M.D., says ophthalmic care lends itself to telehealth because it is image based. As with many other areas of medicine, the COVID-19 pandemic accelerated adoption.

Delivering medication in the suprachoroidal space would be less invasive than intravitreal injections used to deliver many eye treatments.

Racial disparities in glaucoma care persist, regardless of socioeconomic status, finds new research presented at the annual meeting of the American Academy of Ophthalmology.

Private equity (PE) can bring capital investment to retina specialty practices and significantly increase the incomes of the physicians, said a proponent during a debate on private equity at the AAO meeting. The retina specialist arguing against PE said physicians lose control of their practices and the loyalty of their staff and that profits get prioritized over patients.

In a late breaking session, a one-time gene therapy was found in a phase 2 trial to provide sustained release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. The trial is ongoing.

Suber S. Huang, M.D., MBA, a panelist for a session about late-breaking research, said the presentation about Syfovre complications among patients treated at the Wolfe Eye Clinic in Iowa is one of the most important of this year's annual meeting. Five patients experienced complications from the new drug for geographic atrophy.

Results at 96 weeks were similar to those at 48 weeks. The FDA approved the 8-mg formulation of Eylea (aflibercept) in August 2023.